US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
NVDA
$233.95
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
JNJ
$256.03
▲+0.00%
SPCX
$158.96
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
NVDA
$233.95
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
JNJ
$256.03
▲+0.00%
SPCX
$158.96
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
SAB Biotherapeutics, Inc. - Warrant
(NQ:
SABSW
)
0.0140
UNCHANGED
Delayed Quote
Updated: 2:21 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about SAB Biotherapeutics, Inc. - Warrant
< Previous
1
2
3
4
Next >
SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference
May 04, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11
May 03, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
April 26, 2023
SAB-185, a human IgG1 (polyclonal) antibody therapeutic candidate, demonstrated benefit in sustained symptom resolution in patients with Omicron variants of SARS-CoV-2
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy
April 18, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza
April 13, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors
April 04, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Provides Company Update for Full Year 2022
March 31, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference
January 19, 2023
Conference to take place Feb. 6-9 in New York
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract
January 18, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
January 10, 2023
Study shows SAB’s fully-human polyclonal therapeutic that has potential to delay the onset or progression of type 1 diabetes is well tolerated; next step is investigational new drug (IND) filing
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
January 09, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
January 05, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
December 15, 2022
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
December 07, 2022
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes
November 21, 2022
Study of SAB’s fully-human polyclonal therapeutic to delay onset or progression of type 1 diabetes is the last step before investigational new drug (IND) filing
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
November 15, 2022
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases’ at U.S. Pharma Partnering Summit 2022
November 08, 2022
Eddie Sullivan, Co-Founder, President and CEO, to present as SAB Biotherapeutics continues to execute on its partnering focused business strategy
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference
November 03, 2022
SAB highlights data on SAB-176 for seasonal and pandemic influenza and SAB-185 for COVID-19, showing broad efficacy against highly mutating viruses associated with respiratory disease
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
October 27, 2022
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron
September 28, 2022
SAB’s fully-human polyclonal antibody platform maintains its efficacy against multiple variants of several highly mutating viruses
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
